COGT - Cogent Biosciences issues study updates on bezuclastinib CGT4859
2024-01-09 12:29:32 ET
More on Cogent Biosciences
- Cogent slumps after mid-stage data for rare disorder therapy
- Seeking Alpha’s Quant Rating on Cogent Biosciences
- Historical earnings data for Cogent Biosciences
- Financial information for Cogent Biosciences
For further details see:
Cogent Biosciences issues study updates on bezuclastinib, CGT4859